Showing results (111-120 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2017
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell CarcinomaKevin D Courtney, Jeffrey R Infante, Elaine T Lam, et al.
Clinical Genitourinary Cancer|May 2, 2026
Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell CarcinomaWadih Issa, Nicolas Sayegh, Damla Gunenc, et al.
The Journal of Urology|October 1, 2013
BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinomaPayal Kapur, Alana Christie, Jay D Raman, et al.
International Journal of Radiation Oncology, Biology, Physics|August 5, 2019
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell CancerYuanyuan Zhang, Jonathan Schoenhals, Alana Christie, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2015
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific deathThai H Ho, Payal Kapur, Richard W Joseph, et al.
Clinical Genitourinary Cancer|December 13, 2018
Improved Survival Outcomes for Kidney Cancer Patients With Brain MetastasesI Alex Bowman, Alisha Bent, Tri Le, et al.
European Urology|July 22, 2019
Familial Kidney Cancer: Implications of New Syndromes and Molecular InsightsMaria I Carlo, A Ari Hakimi, Grant D Stewart, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 2026
Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic RCC: Predictors of Prolonged Systemic Therapy BenefitLucian Zhao, Dana Keilty, Soumyajit Roy, et al.
International Journal of Radiation Oncology, Biology, Physics|February 7, 2021
Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 TrialVitaly Margulis, Yuval Freifeld, Laurentiu M Pop, et al.
Cancers|February 13, 2025
Characteristics and Outcomes of T1a Renal Cell Carcinoma Presenting with MetastasisLuke Wang, Melis Guer, Dhruv Puri, et al.
Pageof 18